Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its target price upped by research analysts at Scotiabank from ...
Vutrisiran improved mortality and recurrent CV risks independent of disease severity and improved several other endpoints for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback